Molecular Assessment of Surgical Margins

2003 ◽  
pp. 523-533
Author(s):  
Wayne M. Koch
2007 ◽  
Vol 177 (4S) ◽  
pp. 270-270
Author(s):  
Robert A. Linden ◽  
Adeep Thumar ◽  
Danny Haddad ◽  
Steve N. Dong ◽  
Leonard G. Gomella ◽  
...  

2007 ◽  
Vol 177 (4S) ◽  
pp. 158-158
Author(s):  
Stephana Larre ◽  
Laurent Salomon ◽  
Alexandre De La Taille ◽  
Yves Allory ◽  
Andras Hoznek ◽  
...  

2005 ◽  
Vol 173 (4S) ◽  
pp. 228-228
Author(s):  
David I. Lee ◽  
Justin T. Lee ◽  
David Shepherd ◽  
Harrison M. Abrahams

2005 ◽  
Vol 173 (4S) ◽  
pp. 52-52
Author(s):  
Pierre I. Karakiewicz ◽  
Thomas Steuber ◽  
Paul Perrotte ◽  
Alexander Haese ◽  
Thorsten Schlomm ◽  
...  

2004 ◽  
Vol 171 (4S) ◽  
pp. 273-273
Author(s):  
Wolfgang Horninger ◽  
Hermann Rogatsch ◽  
Andreas P. Berger ◽  
Alexandre Pelzer ◽  
Bob Djavan ◽  
...  

Swiss Surgery ◽  
2001 ◽  
Vol 7 (6) ◽  
pp. 252-255 ◽  
Author(s):  
Ota ◽  
Lin

The primary treatment of resectable CRC is surgical resection. Postoperative adjuvant therapies are recommended when lymph node metastases are found (stage III). There is evidence that about 20% of node negative CRC cases (stage II) are understaged, i.e., they are actually node positive (stage III). New intraoperative procedures (lymphatic mapping and sentinel node identification) that are able to detect occult macro- and micrometastases. Molecular assessment of nodal disease should improve the current staging criteria for colon cancer and could influence recommendation for adjuvant treatment.


Sign in / Sign up

Export Citation Format

Share Document